Quick Answer
enGene Therapeutics Inc. reported Net Income Loss of -$117.30 million for the year ending 2025.
- enGene Therapeutics Inc. showed a decrease of -112.7% in Net Income Loss from 2024 to 2025.
- This data is from enGene Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on December 22, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), enGene Therapeutics Inc.'s Net Income Loss has declined by 379.5%.
- Historical annual values: Fiscal year 2025: -$117.30 million | Fiscal year 2024: -$55.14 million | Fiscal year 2023: -$99.92 million | Fiscal year 2022: -$24.46 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: